Page 9 - Rna News Today

Biotechnology company Moderna reported a profit for the fourth quarter that plunged from last year, reflecting a sharp drop in COVID-19 vaccines sales. However, both earnings per share and revenues for the quarter topped analysts' expectations.

Society learned about the value of mRNA during the COVID-19 pandemic when we saw scientists and medical professionals harness its power to deliver a vaccine for the virus within a year. Now, University of Waterloo pharmacy associate professor Emmanuel Ho has developed a novel nanomedicine loaded with genetic material called small interfering RNAs (siRNA) to fight human immunodeficiency virus (HIV) using gene therapy. These siRNAs regulate which genes or proteins are turned on or off in ou...

NASAs spacecraft grabs 4.5 billion-year-old rocks from asteroid that may reveal the earliest signs of life.

"Learn about the impending shortage of anesthesiologists and certified registered nurse anesthetists, and the impact it will have on healthcare by 2033."

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.

E Fund Management Co. Ltd. reduced its position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 42.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,965 shares of the biotechnology company’s stock after selling 12,499 shares during the quarter. E Fund Management Co. […]

Evidently, even the injury of the public health establishment’s own high priests is not enough to bury COVID vaccine idolatry.

Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The

A team at NDORMS, University of Oxford has developed a new approach to significantly improve the accuracy of RNA sequencing.

4.02.2024 - Cancer patients in the UK are receiving a new therapeutic to help their bodies recognise and fight cancer cells as part of a global trial.